Mass drug administration (MDA) of antibiotics to all children in a community or population has the potential to reduce infectious diseases and reduce childhood mortality globally. However, MDA requires weighing near-term gains against longer-term risks of antibiotic resistance, which would impair treatment of serious bacterial infections; fairly distributing benefits and risks among individuals, communities, and whole societies; obtaining informed consent, and engaging the community.
Mass Administration of Antibiotics: Reaching Clinical and Community Equipoise
Johns Hopkins University
Nelson K. Sewankambo & Paul Kutyabami, Empowering local research ethics review of antibacterial mass administration research, BioMed Central, Sept 2022Read more
Ahmed Alasmar, Alex C. Kong, Anthony D. So & Matthew DeCamp, Ethical challenges in mass drug administration for reducing childhood mortality: a qualitative study, BioMed Central, Sept 2022Read more
Anthony So and Matthew DeCamp, Mass Drug Administration of Antibiotics: Reaching Clinical and Community Equipoise, BioMed Central, June 2022Read more